<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part3">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>3</PartID>
        <PartNumber>Part II</PartNumber>
        <PartSequenceNumber>3</PartSequenceNumber>
        <PartTitle>Chemotherapy</PartTitle>
        <PartChapterCount>6</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap12" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>12</ChapterID>
          <ChapterNumber>Chapter 12</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_12</ChapterDOI>
          <ChapterSequenceNumber>12</ChapterSequenceNumber>
          <ChapterTitle Language="En">Docetaxel</ChapterTitle>
          <ChapterFirstPage>133</ChapterFirstPage>
          <ChapterLastPage>146</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>3</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Courtney</GivenName>
                <GivenName>K.</GivenName>
                <FamilyName>Phillips</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff1_12" CorrespondingAffiliationID="Aff1_12">
              <AuthorName DisplayOrder="Western">
                <GivenName>Daniel</GivenName>
                <GivenName>P.</GivenName>
                <FamilyName>Petrylak</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff1_12">
              <OrgDivision>Division of Medical Oncology</OrgDivision>
              <OrgName>Columbia University Medical Center</OrgName>
              <OrgAddress>
                <City>New York</City>
                <State>NY</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_12" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Despite the widespread use of prostate-specific antigen (PSA) for prostate cancer screening, many patients still present with or develop evidence of progressive, metastatic, or recurrent disease. First-line treatment for these patients has long been androgen deprivation therapy (ADT). Initial ADT usually consists of medical or surgical castration, but these agents fail in a median of 18–24 months, as patients develop castration-resistant prostate cancer (CRPC). Treatment options at this point in disease progression traditionally provided palliation only. Secondary hormonal manipulations can produce PSA responses, and the standard chemotherapy combination of mitoxantrone and prednisone can ameliorate symptoms but neither approach ever produced better survival than prednisone alone. Docetaxel-based chemotherapy is the first treatment regimen demonstrated to increase survival in patients with CRPC. The exact timing of treatment in the spectrum of CRPC and duration of docetaxel therapy remains controversial. This chapter reviews the use of docetaxel in prostate cancer, discusses the optimal timing of chemotherapy, and highlights the future directions in taxane-combination therapy involving novel investigational uses.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Docetaxel</Keyword>
            <Keyword>Chemotherapy</Keyword>
            <Keyword>Survival</Keyword>
            <Keyword>Castration-resistant prostate cancer</Keyword>
          </KeywordGroup>
          <ArticleNote Type="Misc">
            <SimplePara>An erratum to this chapter can be found at <ExternalRef>
                <RefSource>http://dx.doi.org/10.1007/978-1-60327-829-4_37</RefSource>
                <RefTarget Address="10.1007/978-1-60327-829-4_37" TargetType="DOI"/>
              </ExternalRef>
            </SimplePara>
          </ArticleNote>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Approximately 186,320 were diagnosed with prostate cancer in the USA in 2008, and another 28,660 men died of their disease, making prostate cancer the most common malignancy in men and the second leading cause of cancer-related deaths in men [<CitationRef CitationID="CR1_12">1</CitationRef>]. Due to prostate-specific antigen (PSA) screening, the vast majority of patients are diagnosed while the disease is still clinically localized. These patients have a number of therapeutic options available depending on risk factors and life expectancy, including radical prostatectomy (open, laparoscopic, or robotic), external beam radiation with or without androgen deprivation, brachytherapy, active surveillance, and watchful waiting. Additionally, ablative technologies, such as high-intensity focused ultrasound (HIFU) and cryoablation, are being utilized in select patients at specialty centers.</Para>
            <Para TextBreak="No">Despite the widespread use of PSA screening, many patients still present with or develop evidence of progressive, metastatic, or recurrent disease. First-line treatment for these patients has long been androgen deprivation therapy (ADT). Initial ADT usually consists of medical or surgical castration [<CitationRef CitationID="CR2_12">2</CitationRef>], but these agents fail in a median of 18–24 months, as patients develop castration-resistant prostate cancer (CRPC) [<CitationRef CitationID="CR3_12">3</CitationRef>]. Treatment options at this point in disease progression traditionally provided palliation only. Secondary hormonal manipulations can produce PSA responses, and the standard chemotherapy combination of mitoxantrone and prednisone can ameliorate symptoms but neither approach ever produced better survival than prednisone alone [<CitationRef CitationID="CR4_12">4</CitationRef>, <CitationRef CitationID="CR5_12">5</CitationRef>]. Two randomized trials published in 2004 demonstrated that docetaxel therapy improved survival in men with CRPC, changing the paradigm that chemotherapy is both toxic and ineffective. This chapter reviews the use of docetaxel in prostate cancer and reviews novel investigational uses.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Initial Studies of Taxane-Based Therapy in Prostate Cancer</Heading>
            <Para TextBreak="No">Paclitaxel, derived from the bark of the Pacific yew tree (<Emphasis Type="Italic">Taxus brevifolia</Emphasis>) stabilizes microtubules and prevents depolymerization, resulting in cell cycle arrest in σ<Subscript>2</Subscript>m [<CitationRef CitationID="CR6_12">6</CitationRef>–<CitationRef CitationID="CR8_12">8</CitationRef>]. Early clinical studies utilizing paclitaxel in advanced, drug-resistant ovarian, breast, and non-small cell lung cancers demonstrated promising activity [<CitationRef CitationID="CR9_12">9</CitationRef>]. Initial trials utilizing single-agent paclitaxel for CRPC, however, did not demonstrate significant efficacy. In an ECOG phase II trial, paclitaxel was administered every 3 weeks to 23 patients with bidimensionally measurable CRPC [<CitationRef CitationID="CR10_12">10</CitationRef>]. Of the 23 patients, only 21 were evaluable due to two early trial deaths. There were no patients who experienced a complete response and only one patient experienced a 9-month partial response. Of the remaining 20 patients, 11 had stable disease, whereas another 9 patients progressed despite treatment. Overall median survival was only 9 months, with two deaths from drug toxicity. Though the authors acknowledge that their inclusion criteria selected patients with extremely advanced and aggressive disease, these results initially discouraged further investigation of taxanes in CRPC.</Para>
            <Para TextBreak="No">Despite initial poor single-agent activity, attempts to utilize paclitaxel for CRPC were revisited when preclinical studies demonstrated that the addition of estramustine to paclitaxel or vinblastine resulted in increased anticancer activity in vitro [<CitationRef CitationID="CR11_12">11</CitationRef>, <CitationRef CitationID="CR12_12">12</CitationRef>]. The results of three clinical trials utilizing estramustine and vinblastine showed PSA response rates of 34–54% and a 31% partial response rate [<CitationRef CitationID="CR13_12">13</CitationRef>–<CitationRef CitationID="CR15_12">15</CitationRef>]. Phase I dose escalation studies examining the efficacy of the paclitaxel-estramustine combination utilized a 96-h continuous infusion of paclitaxel with daily oral estramustine [<CitationRef CitationID="CR16_12">16</CitationRef>]. Using the established dose of 120 mg/m<Superscript>2</Superscript> of paclitaxel, phase II studies utilizing the 96-h infusion strategy showed greater activity with the drug combination than with either single agent alone [<CitationRef CitationID="CR10_12">10</CitationRef>, <CitationRef CitationID="CR17_12">17</CitationRef>]. Another phase I study of weekly paclitaxel established the maximal tolerated dose (MTD) of paclitaxel at 60–107 mg/m<Superscript>2</Superscript>; however, the estramustine used in this protocol produced a 33% rate of discontinuation of therapy due to thrombotic or gastrointestinal toxicity [<CitationRef CitationID="CR18_12">18</CitationRef>].</Para>
            <Para TextBreak="No">Docetaxel, synthesized from the rapidly renewable leaves of the <Emphasis Type="Italic">Taxus baccata</Emphasis> tree, also possesses potent antimitotic activity [<CitationRef CitationID="CR19_12">19</CitationRef>–<CitationRef CitationID="CR21_12">21</CitationRef>]. When compared to paclitaxel, docetaxel has significantly longer absorption coupled with slower efflux [<CitationRef CitationID="CR22_12">22</CitationRef>]. It is clinically active against several malignancies including anthracycline-resistant advanced breast cancer, non-small cell lung cancer, ovarian cancer, and pancreatic cancer. The dose-limiting toxicity of docetaxel is neutropenia, and side effects such as fluid retention can be adequately managed with steroid premedication. An additional benefit is that, unlike paclitaxel, docetaxel does not need to be administered in cremophor.</Para>
            <Para TextBreak="No">Preclinical studies revealed that in vitro, docetaxel was cytotoxic to androgen-dependent LnCAP cells as well as androgen-independent PC-3, and DU145 cells. Docetaxel also appeared to be more active than paclitaxel and could be effectively combined with other agents [<CitationRef CitationID="CR23_12">23</CitationRef>, <CitationRef CitationID="CR24_12">24</CitationRef>]. This compelling evidence laid enough groundwork to justify clinical trials examining the efficacy of docetaxel for CRPC. In stark contrast to the ECOG single-agent paclitaxel study, a single-agent docetaxel study showed significant activity in CRPC [<CitationRef CitationID="CR25_12">25</CitationRef>]. In this study, 35 patients received a median of six doses of docetaxel administered at 75 mg/m<Superscript>2</Superscript> every 3 weeks. A total of 20% of patients experienced a PSA decrease of greater than 80%, while 46% had &gt;50% decrease in PSA. Of the 25 patients with measurable disease, there was one complete response, three near complete responses, and three partial responses with a median response rate of 9 months. The overall survival was 27 months.</Para>
            <Para TextBreak="No">Phase I studies demonstrated that estramustine could be combined with docetaxel. A study by Petrylak et al. combined estramustine 280-mg PO TID for 5 days with escalating doses of docetaxel. The recommended phase II dose of docetaxel combined with estramustine was 70 mg/m<Superscript>2</Superscript> as in minimally pretreated patients and 60 mg/m<Superscript>2</Superscript> in extensively pretreated patients [<CitationRef CitationID="CR26_12">26</CitationRef>]. The dose-limiting toxicities were primarily hematologic. There was a 63% overall rate of ≥50% PSA decline while 28% of the patients with bidimensionally measurable disease experienced a partial response to treatment. The median survival was of 22.8 months, with 21% of patients surviving more than 30 months. Kreis and colleagues’ phase I study of docetaxel and estramustine also established 70 mg/m<Superscript>2</Superscript> as the MTD for phase II studies [<CitationRef CitationID="CR27_12">27</CitationRef>]. In this study, 82% of patients experienced a PSA decrease of more than 50% and there was one soft tissue partial response. A phase II study at Columbia University Medical Center treated 31 chemotherapy naïve patients with estramustine three times daily on days 1–5 of a 21-day cycle along with docetaxel 70 mg/m<Superscript>2</Superscript> on day 2 [<CitationRef CitationID="CR28_12">28</CitationRef>]. The most serious side effects were vascular and included three deep venous thromboses. The most commonly observed grade 3 and 4 adverse events were neutropenia and fatigue. At the time of publication 18 of the phase II patients were evaluable for response. Of these, 84% had PSA declines of ≥50% while 61% had PSA declines of more than 75%. These results were supported by a phase II study in the CALGB (Cancer and Leukemia Group B) combining docetaxel, estramustine, and hydrocortisone [<CitationRef CitationID="CR29_12">29</CitationRef>]. In this study, there was a 3% complete response rate and a 20% partial response rate. A total of 69% of patients experienced a ≥50% decline in PSA while 54% had a decrease of 75% or more, all with manageable toxicity. These studies provided the rationale for evaluating single-agent and combination docetaxel therapy in two large phase III studies.</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>TAX 327</Heading>
            <Para TextBreak="No">TAX 327 was an international, randomized, open-label phase III study comparing two schedules of docetaxel plus prednisone to mitoxantrone plus prednisone for the treatment of metastatic CRPC [<CitationRef CitationID="CR30_12">30</CitationRef>]. To qualify for inclusion, patients were required to have evidence of disease progression while on ADT and were not permitted to have received prior radioisotope treatment. Patients who had received any chemotherapy other than estramustine and corticosteroids were also excluded, and all patients were withdrawn from antiandrogens. Patients were randomized to one of three arms. The first group (D3P) received docetaxel 75 mg/m<Superscript>2</Superscript> every 3 weeks with prednisone 5 mg twice daily (up to ten cycles); the second group (D1P) received docetaxel 30 mg/m<Superscript>2</Superscript> weekly with prednisone 5 mg twice daily (up to five cycles of 6 weeks each); and the third group (MP) received mitoxantrone 12 mg/m<Superscript>2</Superscript> every 3 weeks with prednisone 5 mg twice daily (up to ten cycles). The primary endpoint of this study was overall survival while secondary endpoints included serum PSA decrease of at least 50%, objective tumor response, improvement in quality of life scores, and decrease in pain.</Para>
            <Para TextBreak="No">A total of 1,006 patients were randomized into the study. Baseline characteristics between the groups were similar. In the initial 2004 report, the median follow-up was 20.8 months for patients receiving docetaxel every 3 weeks, and 20.7 months for patients in the other two groups. Overall median survival was 18.9 months for D3P patients, which differed significantly from the 16.5-month survival seen in the MP arm (<Emphasis Type="Italic">p</Emphasis> = 0.009). There was no significant difference in survival between MP and D1P patients (median survival 17.4 months, <Emphasis Type="Italic">p</Emphasis> = 0.36). A multivariate analysis revealed that visceral involvement, high baseline alkaline phosphatase, anemia and, on post-hoc analysis, Gleason grade 8–10 were negative prognostic factors.</Para>
            <Para TextBreak="No">Pain reduction occurred more frequently in the D3P arm than the MP arm (35% vs. 22%, respectively, <Emphasis Type="Italic">p</Emphasis> = 0.01). Thirty-one percent of patients in the weekly docetaxel group reported palliation of pain symptoms; this was not significantly different from either of the other two groups. Both docetaxel arms had significantly higher rates of PSA response (45% for the D3P group, 48% for the D1P group; <Emphasis Type="Italic">p</Emphasis> &lt; 0.001) than the mitoxantrone arm (32%). Neither the median duration of PSA response (7.7–8.2 months) nor the change in volume of soft tissue disease varied significantly between any of the groups.</Para>
            <Para TextBreak="No">Only 815 patients could be evaluated for quality of life changes because the FACT-P questionnaire was not available in all patients’ languages. In this intent-to-treat analysis, a quality of life response was defined as a 16-point improvement from baseline on two surveys administered at least 3 weeks apart. Only 13% of MP patients reported quality of life response. This was significantly less than both the D3P and D1P arms, in which 22% (<Emphasis Type="Italic">p</Emphasis> = 0.009) and 23% (<Emphasis Type="Italic">p</Emphasis> = 0.005) of patients, respectively, reported improvements. In a subset analysis, patients receiving docetaxel exhibited the greatest improvement in factors directly related to the prostate.</Para>
            <Para TextBreak="No">The overall incidence of grade 3 and 4 neutropenia was low for all three study arms: the incidence was higher in the D3P group (3%) than the D1P group (0%) and the mitoxantrone group (0.9%). Two patients died of sepsis: one in a docetaxel group and one in the mitoxantrone group. No patients received concomitant colony stimulating factors. Deterioration of cardiac function was significantly higher in the mitoxantrone group; however, patients receiving docetaxel on either schedule had higher rates of one or more serious adverse events (26% and 29%, respectively) than patients receiving mitoxantrone (20%). Despite this, three of the five deaths, which were likely to be treatment related, were in the mitoxantrone group.</Para>
            <Para TextBreak="No">In October 2006, a follow-up survival analysis was performed [<CitationRef CitationID="CR31_12">31</CitationRef>]. Median survival times were not significantly different from the initial report, and D3P continued to demonstrate a survival benefit over mitoxantrone-based therapies (<Emphasis Type="Italic">p</Emphasis> = 0.004). Median survival times were 19.2 months in the D3P arm, 17.8 months in the D1P arm, and 16.3 months in the MP arm. Three-year survival rates were significantly higher in DP1-treated patients (17.2%) than in mitoxantrone-treated patients (12.8%) (<Emphasis Type="Italic">p</Emphasis> = 0.005). A subset analysis showed that this survival benefit persisted in men both above and below the age of 65 years, as well as those who did and did not have baseline pain symptoms and those who had baseline PSA’s above and below the median PSA value of 115 ng/ml.</Para>
            <Para TextBreak="No">An additional analysis of patients who crossed over from docetaxel-based treatment to mitoxantrone-based treatment and vice versa was also reported [<CitationRef CitationID="CR32_12">32</CitationRef>]. There were 89 D3P patients and 76 D1P patients who crossed over to the MP group. Another 68 patients crossed over from mitoxantrone-based therapy to docetaxel-based therapies, schedules of which were varied and/or unspecified. Though there were no significant differences in performance status between groups in the initial study, men who crossed over from docetaxel to mitoxantrone had lower Karnofsky performance scores, higher pain scores, and higher serum alkaline phosphatase and PSA levels than patients crossing from mitoxantrone to docetaxel. The median follow-up after cross over was 11 months, and the median survival for patients crossing in either direction was 10 months. PSA data after cross over was available for 96 patients. After cross over, 9.8, 22.2, and 28% of patients starting in the D3P, D1P, and MP group, respectively, experienced a 50% or greater reduction in PSA. Any degree of PSA reduction was experienced in 34, 37, and 72% of patients, respectively; however, the overall median PSA progression-free survival (PFS) was brief (3.2, 3.7, and 5.9 months, respectively). The authors did not find a correlation between response to first-line chemotherapy and response to second-line chemotherapy though they acknowledged that their sample sizes were too small for such an analysis. A phase II study examining men given D3P after progression on mitoxantrone and prednisone has since been reported [<CitationRef CitationID="CR33_12">33</CitationRef>]. Though small, this study reported that more than 60% of men had a reduction in pain and 57% of men experienced a PSA decrease of at least 50%. Median PFS was 5 months, and median overall survival was 15 months.</Para>
            <Para TextBreak="No">One of the more puzzling outcomes of TAX 327 was the discrepancy seen between the D3P and D1P administration schedules. It is known that docetaxel clearance is affected by liver function, body surface area, age, and CYP3A4 function [<CitationRef CitationID="CR34_12">34</CitationRef>], and, consistent with the TAX 327 results, it has been found that weekly administration schedules often have lower rates of adverse events, particularly myelosuppression [<CitationRef CitationID="CR35_12">35</CitationRef>]. What is important to remember, however, about the TAX 327 trial, is that the study was not powered or designed to compare the D3P and D1P arms. As such, it is impossible to compare the two to each other [<CitationRef CitationID="CR36_12">36</CitationRef>]. Despite the fact that weekly docetaxel did not result in increased survival, there was a significant improvement in quality of life, pain response and PSA response over mitoxantrone-based therapies.</Para>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>SWOG 99-16</Heading>
            <Para TextBreak="No">SWOG Intergroup protocol 99-16 (SWOG 99-16) was a multicenter, randomized, nonblinded clinical trial published at the same time as TAX 327 [<CitationRef CitationID="CR37_12">37</CitationRef>]. Based on the synergistic anticancer effects of estramustine and docetaxel in vitro [<CitationRef CitationID="CR24_12">24</CitationRef>], as well as phase I and II trials examining docetaxel in men [<CitationRef CitationID="CR28_12">28</CitationRef>], SWOG 99-16 was designed to compare docetaxel and estramustine (DE) with mitoxantrone and prednisone (MP). Both regimens were administered in 21-day cycles. Estramustine 280 mg was given three times a day on days 1–5; 60 mg/m<Superscript>2</Superscript> of docetaxel was given on day 2 with dexamethasone pretreatment. Patients recruited after January 15, 2001 also received warfarin (2 mg daily) and aspirin 325 mg daily, after a report showed that this regimen would decrease thrombotic events. Patients in the MP arm received 12 mg/m<Superscript>2</Superscript> of mitoxantrone on day 1 and prednisone 5 mg twice daily. Doses were escalated to 70 mg/m<Superscript>2</Superscript> of docetaxel or 14 mg/m<Superscript>2</Superscript> of mitoxantrone if there were no grade 3 or 4 adverse events in the first cycle. Patients were eligible for inclusion in this study if they had biochemical or radiologic progression of metastatic CRPC. As with the TAX 327 study, patients who had received radioisotopes were ineligible, and antiandrogens were discontinued. Patients were, however, still eligible if they had received one prior systemic therapy as long as that therapy was stopped more than 4 weeks prior and did not include estramustine, anthracyclines, mitoxantrone, or taxanes. The primary endpoint of SWOG 99-16 was overall survival while PFS, objective response rates, and PSA decreases of 50% or more were secondary endpoints. A total of 770 patients were enrolled into this study; 96 patients were subsequently found to be ineligible, primarily due to inadequate antiandrogen withdrawal. The baseline characteristics of the 674 eligible patients were similar in all study arms. Patients were followed for a median of 32 months. In that time, 64% of the patients in the DE group and 70% of the patients in the MP group died. In an intent-to-treat analysis, the median survival for docetaxel patients was significantly longer than mitoxantrone patients (17.5 months vs. 15.6 months, <Emphasis Type="Italic">p</Emphasis> = 0.02). The median time to progression was significantly longer in the DE group (6.3 months) than in the MP group (3.2 months, <Emphasis Type="Italic">p</Emphasis> &lt; 0.001). Additionally, while 50% of patients receiving docetaxel had PSA decreases of at least 50%, only 27% of patients receiving mitoxantrone exhibited this decrease (<Emphasis Type="Italic">p</Emphasis> &lt; 0.001). There was no significant difference in measurable disease response.</Para>
            <Para TextBreak="No">Over the course of the study, docetaxel resulted in significantly higher rates of neutropenic fevers, cardiovascular events, nausea and vomiting, metabolic alterations, and neurologic events. There were no significant differences in rates of grade 3–5 neutropenia between the groups. There were eight deaths attributed to docetaxel treatment and four related to mitoxantrone.</Para>
            <Para TextBreak="No">Quality of life and pain scores for patients in SWOG 99-16 were reported in 2006 [<CitationRef CitationID="CR38_12">38</CitationRef>]. SWOG 99-16 utilized the McGill Pain Questionnaire’s Present Pain Intensity scale as well as the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire C30. Unlike TAX 327, there were no significant differences in pain or quality of life scores between the two SWOG 99-16 study arms.</Para>
          </Section1>
          <Section1 ID="Sec5">
            <Heading>Clinical Implications of TAX 327 and SWOG 99-16</Heading>
            <Para TextBreak="No">SWOG 99-16 and TAX 327 were the first trials to demonstrate the survival benefit of taxane-based chemotherapy for CRPC. Though it remains unclear why weekly docetaxel did not result in the same survival benefit as docetaxel administered every 3 weeks, it is clear that therapy with docetaxel represents a significant improvement over mitoxantrone-based therapy. What remains unclear, however, is whether docetaxel is more effective when administered with prednisone or estramustine. The agent administered with docetaxel may impact pain and quality of life more than the docetaxel itself, explaining the discrepancy between the two trials, and a direct comparison of SWOG 99-16 and TAX 327 has too many confounding factors to be valid [<CitationRef CitationID="CR39_12">39</CitationRef>]. Today, a clinical trial comparing estramustine and prednisone is unlikely to be conducted because agents less toxic than estramustine have been introduced in the interim. Additionally, because patients both with and without pain and measurable disease were included, it is not yet clear at what point in disease progression patients are most likely to benefit from taxane-based therapy. Only when more specific markers of response become available can optimal treatment timing be studied.</Para>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>Optimal Timing of Chemotherapy</Heading>
            <Para TextBreak="No">While the utility of docetaxel for CRPC is clear, the point in disease progression that it should be administered is controversial. Because SWOG 99-16 and TAX 327 included both symptomatic and asymptomatic patients, the question of the optimal timing of chemotherapy administration was not addressed by either study. There are two main questions that arise regarding the appropriate timing of cytotoxic therapy. First, can cytotoxic therapy prevent or delay the progression from androgen-sensitive prostate cancer to CRPC? And secondly, should cytotoxic chemotherapy be administered as soon as there is evidence of CRPC or once disease becomes symptomatic? [<CitationRef CitationID="CR3_12">3</CitationRef>].</Para>
            <Para TextBreak="No">To date, the evidence supporting the hypothesis that cytotoxic therapy can prevent the development of CRPC is primarily preclinical. Whether hormone insensitive cells exist prior to androgen ablation or develop soon thereafter is unclear. What is apparent is that soon after ADT is initiated, cells resistant to apoptosis become predominant. The molecular mechanisms behind this are thought to be largely regulated by the ratios of bax, a proapoptotic protein, and bcl-2, an antiapoptotic protein [<CitationRef CitationID="CR40_12">40</CitationRef>]. In rat castration models, it has been shown that immediately after androgen deprivation, the ratio of bax to bcl-2 increases, favoring apoptosis [<CitationRef CitationID="CR41_12">41</CitationRef>]. A few days later, however, this ratio rapidly reverses implying that cells resistant to apoptosis are increasing in number. In LnCaP xenograft models, mice that received paclitaxel and castration simultaneously fared better than those that received sequential therapy [<CitationRef CitationID="CR42_12">42</CitationRef>]. Mice in this study that were castrated after cytotoxic therapy had much poorer outcomes. This is in contrast to an SCID mouse line injected with LnCaP cells; the mice receiving docetaxel prior to castration developed the smallest tumors [<CitationRef CitationID="CR43_12">43</CitationRef>]. To date, there has been only one human study done to address this question [<CitationRef CitationID="CR44_12">44</CitationRef>]. In 2005, Hussain and colleagues published their experience administering docetaxel every 3 weeks (up to six cycles) to 39 men who had experienced a biochemical recurrence after primary therapy. Of the men enrolled, 32 initially had PSA-only recurrence while the remaining 7 also had clinical evidence of metastasis. All of these men had noncastrate testosterone levels. All men received docetaxel and 33 went on to receive 4–12 months of complete androgen blockade with subsequent peripheral androgen blockade. After treatment with docetaxel, the median PSA was 5.7 ng/ml and 48.5% had a ≥50% decrease in PSA while 20% had a ≥75% decrease. With total androgen blockade, all patients achieved completely castrate levels of testosterone with a median PSA of 0.1 ng/ml. After peripheral androgen blockade, PSA remained at 0.1 ng/ml. Median time from end of treatment to the last follow-up for the 33 patients who had received androgen ablation was 26 months. After a median of 2.3 months, 28 of the 33 men’s PSA rose to a median of 0.41 ng/ml, whereas 5 others remained at a stable 0.1 ng/ml. Three of these five patients had started off with clinical evidence of metastatic disease.</Para>
            <Para TextBreak="No">Contrary to the body of work done on androgen-dependent prostate cancer, there has been little research done to determine the optimal timing of docetaxel in CRPC. Generally speaking, cytotoxic therapy can be initiated when the PSA first rises on ADT, when radiologic evidence of metastatic disease develops, or when patients become symptomatic. The vast majority of chemotherapy trials have included both symptomatic and asymptomatic patients as well as those with bone metastasis only and bidimensionally measurable disease. A small phase III trial conducted by Berry and coworkers examined the impact of mitoxantrone and prednisone vs. prednisone alone in patients with asymptomatic CRPC [<CitationRef CitationID="CR45_12">45</CitationRef>]. Though the addition of mitoxantrone in these patients increased median time to progression and the percent of patients achieving a PSA response, mitoxantrone did not result in an overall survival benefit and the impact of early treatment could not be assessed. About 19% of the patients enrolled in SWOG 99-16 and 21% of the patients enrolled in TAX 327 had asymptomatic CRPC without evidence of metastasis [<CitationRef CitationID="CR3_12">3</CitationRef>, <CitationRef CitationID="CR27_12">27</CitationRef>, <CitationRef CitationID="CR30_12">30</CitationRef>]. A subgroup analysis of asymptomatic TAX 327 patients revealed that these patients derived the same survival benefit from docetaxel as the group overall [<CitationRef CitationID="CR46_12">46</CitationRef>, <CitationRef CitationID="CR47_12">47</CitationRef>]. When Oudard and coworkers retrospectively examined patients with metastatic CRPC who had received chemotherapy, they did find a significant difference in survival between patients with PSA doubling times above and below 45 days [<CitationRef CitationID="CR48_12">48</CitationRef>]. Patients with metastatic disease, however, are a very heterogeneous group, and it still remains unclear which patients within this subgroup may derive the most benefit from early cytotoxic intervention.</Para>
          </Section1>
          <Section1 ID="Sec7">
            <Heading>Future Directions in Taxane-Combination Therapy</Heading>
            <Section2 ID="Sec8">
              <Heading>Antiangiogenesis Agents</Heading>
              <Para TextBreak="No">It has long been known that tumors cannot proliferate without developing neovasculature to support this growth [<CitationRef CitationID="CR49_12">49</CitationRef>]. Angiogenesis has therefore been an attractive target of antitumor therapies. Early on in taxane studies, it was noted that the taxanes have direct effects on angiogenesis as well. In 2001, Sweeney and colleagues reported that docetaxel inhibited the growth of human umbilical vein endothelial cells (HUVEC) [<CitationRef CitationID="CR50_12">50</CitationRef>]. This inhibition was temporized when vascular endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF) was added to the HUVEC culture medium. The effect of VEGF and bFGF was reversed by a soluble recombinant human monoclonal antibody to VEGF (rhuMAb-VEGF). Similar results were found in in vivo Matrigel models: docetaxel was able to directly inhibit angiogenesis, and while this effect was abrogated by the addition of VEGF and bFGF, rhuMAb-VEGF was able to restore antiangiogenesis activity.</Para>
              <Para TextBreak="No">This study, along with others demonstrating that cyclophosphamide, vinblastine, paclitaxel, and docetaxel have antiangiogenic properties in vivo, sets the stage for clinical trials combining targeted antiangiogenic agents with these cytotoxic agents [<CitationRef CitationID="CR51_12">51</CitationRef>]. Moreover, the correlation of elevated serum levels of VEGF with poor prognosis in men with CRPC further justified targeting angiogenesis in these patients. Monoclonal antibodies, which bind VEGF, are currently under evaluation in combination with docetaxel chemotherapy in men with CRPC. Picus et al. treated 79 men with CRPC with docetaxel 70 mg/m<Superscript>2</Superscript> every 3 weeks, estramustine 280-mg PO TID for 5 days, and bevacizumab 15 mg/kg day 2 [<CitationRef CitationID="CR25_12">25</CitationRef>]. The 23-month median survival reported in this study supported the design of a phase III study in the CALGB comparing docetaxel 75 mg/m<Superscript>2</Superscript> every 3 weeks, prednisone 5-mg PO twice daily, and bevacizumab 15 mg/kg IV on day 1 every 3 weeks with docetaxel combined with prednisone. A second trial evaluated the combination of bevacizumab and docetaxel in patients who exhibited disease progression on docetaxel. This phase II study of heavily pretreated patients administered bevacizumab 10 mg/kg and docetaxel 60 mg/m<Superscript>2</Superscript> every 3 weeks [<CitationRef CitationID="CR52_12">52</CitationRef>]. All of the 20 patients had bone metastasis and 8 had bidimensionally measurable disease. Of those treated, 11 (55%) exhibited major PSA responses and 3 had objective responses. Of the 11 patients exhibiting major PSA responses, 4 had not had any PSA response to docetaxel alone. Aflibercept (VEGF Trap), a protein constructed to include the extracellular domains of human VEGF receptor 1 and 2 fused to the constant region (Fc) of human IgG1 antibody, functions as a soluble decoy receptor that effectively binds VEGF-A. The VENICE trial, employing a similar design to the CALGB study, compares docetaxel combined with prednisone and aflibercept 6 mg/kg IV to docetaxel and prednisone. It is designed to detect an improvement in median survival from 19 to 23 months.</Para>
              <Para TextBreak="No">Immunomodulators (IMiDs), such as thalidomide and lenolidamide, are currently being evaluated in combination with docetaxel. In addition to antiangiogenic effects, IMiDs also possess immunomodulatory and anti-inflammatory activity. Preclinical studies have demonstrated that lenalidomide both alone and in combination with docetaxel significantly increases apoptosis in PC-3 cells [<CitationRef CitationID="CR53_12">53</CitationRef>]. A phase I study looking at low-dose metronomic therapy combination of docetaxel and thalidomide concluded that the MTD was thalidomide 100 mg twice daily and docetaxel 25 mg/m<Superscript>2</Superscript> weekly [<CitationRef CitationID="CR54_12">54</CitationRef>]. To further evaluate this combination, a randomized phase II study designed by Figg et al. compared weekly docetaxel to the combination of docetaxel and thalidomide. Although the primary endpoint of this trial was to evaluate the increase in toxicity of adding thalidomide to docetaxel, and not to detect a survival difference, the reported median survival of 28.9 months for docetaxel combined with thalidomide is the highest median survival reported for a phase II study to date.</Para>
              <Para TextBreak="No">More recently, another phase II trial evaluated the combination of thalidomide 200 mg daily, docetaxel 75 mg/m<Superscript>2</Superscript> every 3 weeks, and bevacizumab 15 mg/kg every 3 weeks [<CitationRef CitationID="CR55_12">55</CitationRef>]. All 60 patients were chemotherapy naïve. A total of 41 patients experienced PSA declines of &gt;80%, and 51 patients had PSA declines of &gt;50%. In patients with measurable disease, there were 2 complete responses, 18 partial responses, 11 stable diseases, and 1 progressive disease for an overall response rate of 63%. The estimated PFS was 18.2 months. Five patients experienced febrile neutropenia, five experienced syncope, three had gastrointestinal perforation or fistula formation, three developed thrombosis, and two had grade 3 bleeding.</Para>
              <Para TextBreak="No">Sorafenib and sunitinib are multi-tyrosine kinase inhibitors that act on pathways, which regulate cell division, survival, and apoptosis. Their antiangiogenic properties come from their affinity for VEGF receptors. Though both drugs are already approved and indicated for other solid malignancies, testing of these agents in prostate cancer has just begun. Sunitinib alone and in combination has been shown to inhibit growth in both DU-145 and PC-3 prostate cancer xenografts [<CitationRef CitationID="CR56_12">56</CitationRef>, <CitationRef CitationID="CR57_12">57</CitationRef>]. In a preliminary report of an ongoing phase II study of sunitinib, docetaxel, and prednisone in patients with metastatic CRPC, 5 of the 18 evaluable patients have discontinued the study [<CitationRef CitationID="CR58_12">58</CitationRef>]. Thus far, there is a 50% PSA response rate, and 39% of the patients with measurable disease have had partial responses. An additional 54% have stable disease. Currently, phase II studies are also underway examining the efficacy of docetaxel and sorafenib, while sunitinib is being studied as first-line chemotherapy in combination with prednisone and docetaxel and as second-line chemotherapy after progression on docetaxel [<CitationRef CitationID="CR59_12">59</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec9">
              <Heading>Calcitriol Combination Therapy</Heading>
              <Para TextBreak="No">Calcitriol (1,25-dihydrocholecalciferol, 1,25(OH)<Subscript>2</Subscript>-D<Subscript>3</Subscript>) is a biologically active form of vitamin D with known activity against a number of malignancies. Preclinical studies have demonstrated that calcitriol is able to inhibit the mitogenesis of prostate cancer cell lines, and combination studies performed in vitro and in vivo have confirmed that it enhances the antitumor effects of paclitaxel [<CitationRef CitationID="CR60_12">60</CitationRef>–<CitationRef CitationID="CR62_12">62</CitationRef>]. Though relatively safe, the dose-limiting toxicity of calcitriol is hypercalcemia. A formulation of calcitriol, DN-101, has been created to overcome this limitation. DN-101 is designed to be administered in pulsed weekly doses, which prevents much of its adverse affects. After a single institution phase II trial demonstrated promising results using weekly pulsed calcitriol and docetaxel [<CitationRef CitationID="CR63_12">63</CitationRef>], a second double-blinded, randomized trial, the Androgen Insensitive Prostate Cancer Study of Calcitriol Enhancing Taxotere (ASCENT) trial was conducted [<CitationRef CitationID="CR64_12">64</CitationRef>]. This study compared treatment with docetaxel and placebo with docetaxel and DN-101. The primary endpoint of the trial was proportion of patients experiencing at least a 50% reduction in serum PSA. Overall survival, decrease in measurable disease, safety, and tolerability as well as PSA, tumor, and clinical PFS were secondary outcomes. The median follow-up was 18.3 months. There was no significant difference between the two groups in primary endpoint (<Emphasis Type="Italic">p</Emphasis> = 0.16), skeletal morbidity-free survival (<Emphasis Type="Italic">p</Emphasis> = 0.13), or measurable disease (<Emphasis Type="Italic">p</Emphasis> = 0.51). A survival analysis performed after adjusting for differences in hemoglobin and ECOG performance status, however, demonstrated that patients receiving docetaxel and DN-101 had an improvement in survival when compared to the docetaxel placebo group (<Emphasis Type="Italic">p</Emphasis> = 0.04). At the time of analysis, median survival in the placebo group was 16.4 months, and median survival in the DN-101 group, though not met, was estimated to be 24.5 months. Additionally, gastrointestinal toxicity and incidence of deep venous thrombosis (DVT) was significantly lower in the DN-101 arm (9.6% vs. 2.4% and 7.2% vs. 1.5%, respectively). The difference in the incidence of DVT, while not fully understood, is potentially due to reductions in the procoagulant known as tissue factor [<CitationRef CitationID="CR39_12">39</CitationRef>]. ASCENT II, a phase III study comparing D3P to weekly docetaxel combined with DN-101/D1P, was terminated early due to an increased death rate observed on the experimental arm. Since these findings have yet to be presented or published, the reason for the increased death rate is unknown.</Para>
            </Section2>
            <Section2 ID="Sec10">
              <Heading>Bone-Targeted Therapies</Heading>
              <Para TextBreak="No">Osteoblastic bone metastases are a devastating hallmark of prostate cancer. Because bone metastases and the resulting symptoms have a deleterious impact on quality of life and result in serious complications, bone-targeted therapies have garnered tremendous interest, particularly in combination with docetaxel. The endothelin axis is a signaling cascade pivotal to a number of processes including mitogenesis, pain, survival, vasoconstriction, and bone homeostasis [<CitationRef CitationID="CR65_12">65</CitationRef>, <CitationRef CitationID="CR66_12">66</CitationRef>]. Ligand binding to one of the endothelin receptors (ET<Subscript>A(alpha)</Subscript> or ET<Subscript>B(beta)</Subscript>) results in bone-matrix formation as well as proliferation, invasion, and evasion of apoptosis. One of the bone-targeted agents most actively being studied is atrasentan. Atrasentan is an orally bioavailable inhibitor of endothelin ligand-1<Subscript>A(alpha)</Subscript> (ET-1<Subscript>A(alpha)</Subscript>). In preclinical and clinical trials, atrasentan has been shown to downregulate bone formation, mitosis, angiogenesis, and pain signaling [<CitationRef CitationID="CR67_12">67</CitationRef>]. Atrasentan has been studied as a single agent in several studies. The M96-594 trial compared two doses of atrasentan (10 mg and 2.5 mg) to placebo. Although atrasentan resulted in a significant improvement in time to progression and survival when compared to placebo, when an intent-to-treat analysis was performed, this difference was no longer observed [<CitationRef CitationID="CR68_12">68</CitationRef>]. There were, however, promising improvements in serum alkaline phosphatase and PSA. A follow-up study, M00-211, was performed comparing 10 mg of atrasentan to placebo in men with CRPC and asymptomatic metastatic disease. While there was no significant difference in time to disease progression in the two arms, the subset of men with bone metastasis only disease did experience a significant improvement in serum parameters and quality of life measurements. Since then, preclinical studies have supported the combined use of atrasentan and docetaxel [<CitationRef CitationID="CR69_12">69</CitationRef>], and a phase I/II study has demonstrated its safety in humans. A trial is currently being conducted in SWOG comparing docetaxel and prednisone to docetaxel, prednisone, and atrasentan [<CitationRef CitationID="CR39_12">39</CitationRef>].</Para>
              <Para TextBreak="No">Like atrasentan and the endothelin axis, RANK (receptor activator of NF-κB) ligand and the osteoprotegerin pathway, first garnered interest because of its role in bone homeostasis. This axis was soon recognized to be pivotal in inflammation and the development of metastases. In 2007, Luo and coworkers demonstrated that a mutation, which prevented phosphorylation of the inhibitor of NF-κB kinase α (IκB kinase α or IKKα), increased the sequestration and destruction of NF-κB. Clinically, this mutation delayed and prevented the development of prostate cancer metastases via maspin, a known metastasis suppressor [<CitationRef CitationID="CR70_12">70</CitationRef>, <CitationRef CitationID="CR71_12">71</CitationRef>]. When the RANK ligand inhibitor osteoprotegerin-Fc was coadministered with docetaxel to murine bone metastasis cancer models, survival time was significantly increased and skeletal tumor burden was significantly decreased [<CitationRef CitationID="CR72_12">72</CitationRef>]. A clinical study is underway comparing denosumab (a RANK ligand inhibitor) and zoledronic acid for the treatment of patients with CaP metastases to the bone [<CitationRef CitationID="CR59_12">59</CitationRef>].</Para>
              <Para TextBreak="No">Bortezomib is a dipeptide boronic acid, which also acts on the NF-κB pathway [<CitationRef CitationID="CR73_12">73</CitationRef>]. At the molecular level, bortezomib reversibly inhibits the 26S proteosome, which is responsible for destroying IκB kinase α. Like docetaxel, bortezomib can also downregulate bcl-2 expression. However, unlike docetaxel, bortezomib arrests cells in G1 and G2, whereas docetaxel-treated cells arrest at σ<Subscript>2</Subscript>m [<CitationRef CitationID="CR73_12">73</CitationRef>, <CitationRef CitationID="CR74_12">74</CitationRef>]. In vivo, the combination of bortezomib and docetaxel has been shown to alter bcl-2 and bcl-xL expression and sensitize cell lines to radiation. In phase I and II trials, single-agent bortezomib has had effect on CRPC [<CitationRef CitationID="CR75_12">75</CitationRef>, <CitationRef CitationID="CR76_12">76</CitationRef>]. Subsequently, a phase I/II study demonstrated that, in combination with 40 mg/m<Superscript>2</Superscript> docetaxel, 1.6 mg/m<Superscript>2</Superscript> of bortezomib was safe and tolerable and demonstrated antitumor activity [<CitationRef CitationID="CR73_12">73</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec11">
              <Heading>Vaccine-Taxane Therapy</Heading>
              <Para TextBreak="No">Vaccine-based therapies are one of the most promising, but technically challenging, classes of agents. The theoretical advantage of vaccine therapy is that the use of the body’s own immune system may potentially avoid many of the side effects caused by chemotherapy. Logistically, however, the identification and creation of effective vaccines has been difficult. Antigens must be identified and expressed in a quantity adequate to mount an immune response. The vaccine must be delivered in such a way that it comes in contact with the antigen, and this response must be maintained but cannot incite other more toxic reactions. Several vaccines have been created and tested in malignant diseases. Among these are the carbohydrate and glycoprotein vaccines, which use “self” antigens, such as PSA, MUC-1, and PSMA, to induce a T-cell response directed against the tumor. These vaccines, however, often produce a limited response. Recombinant virus vaccines are much more immunogenic. Recombinant fowlpox expressing PSA (rF-PSA) and recombinant <Emphasis Type="Italic">Vaccinia virus</Emphasis> expressing PSA (rV-PSA) were studied in a randomized phase II study (E7897) in the adjuvant setting after patients were treated for clinically localized disease [<CitationRef CitationID="CR77_12">77</CitationRef>]. Patients were vaccinated four times with one of the two vaccines in varying sequences. Patients receiving one rV-PSA vaccination followed by three vaccinations of rF-PSA, in a “vaccinia prime – avipox boost” strategy, had a significant increase in PSA PFS, supporting the importance of chronology in vaccine administration. In an update of this study after a median of 50 months of follow-up, patients in the prime-boost arm experienced an 18.2 month median time to progression while patients in the other two arms (three rF-PSA vaccinations vs. three rF-PSA vaccinations followed by a single rV-PSA vaccination) progressed at a median of 9.2 and 9.1 months, respectively [<CitationRef CitationID="CR78_12">78</CitationRef>].</Para>
              <Para TextBreak="No">Inciting T-cell immune reactions is a complex process requiring initial antigen presentation via the MHC molecule. A second co-stimulatory molecule, such as B7.1, presented by an antigen-presenting cell (APC) is also required. Because of this, a phase II study in metastatic CRPC patients utilizing a prime-boost vaccination scheme coadministered with a recombinant virus expressing a co-stimulatory molecule was performed [<CitationRef CitationID="CR79_12">79</CitationRef>]. This regimen was compared to another arm receiving the same vaccinations and docetaxel. Twenty-eight patients were ultimately randomized into this study and no patient receiving vaccinations only experienced more than a grade 2 toxicity. PSA-specific T cells were upregulated 3.33-fold in both study arms as determined by ELISPOT assay. Interestingly, the immune response did not remain antigen specific. T cells recognizing other prostate cancer specific antigens were also identified after vaccination. Serum PSA declines were modest in both scope and degree (3/14 patients in the vaccine only arm and 6/14 in the vaccine/docetaxel arm). Although the study was not powered to detect differences in PFS, patients receiving only vaccine had a median PFS of 1.8 months, while patients receiving combination therapy had a median PFS of 3.2 months. Thus, as newer vaccines are developed, the use of docetaxel is likely to continue, especially because unlike other chemotherapy agents, such as cyclophosphamide, docetaxel does not inhibit the function of T-regulatory cells but does enhance CD8+ response to CD3 binding [<CitationRef CitationID="CR80_12">80</CitationRef>]. Since prolonged activation of the immune system may result from vaccines, the sequence of chemotherapy and immunotherapy must be considered in clinical trial design.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec12">
            <Heading>Docetaxel and Prostatectomy</Heading>
            <Para TextBreak="No">Though there are many treatment options for men diagnosed with localized prostate cancer, the vast majority undergo surgical resection or radiation; despite the fact that the disease is localized at the time of presentation, approximately 30–40% of patients undergoing prostatectomy will have a PSA recurrence within 10 years of surgery [<CitationRef CitationID="CR81_12">81</CitationRef>]. There have been multiple studies examining the effect of both neoadjuvant and adjuvant treatments on outcomes; however, to date, this approach is considered investigational [<CitationRef CitationID="CR82_12">82</CitationRef>–<CitationRef CitationID="CR85_12">85</CitationRef>].</Para>
            <Para TextBreak="No">Several phase I/II studies have looked at the safety of docetaxel alone or in combination as neoadjuvant treatment for patients with high-risk prostate cancer undergoing prostatectomy [<CitationRef CitationID="CR86_12">86</CitationRef>–<CitationRef CitationID="CR90_12">90</CitationRef>]. Though docetaxel dosing schedules and the duration of treatment have varied, these studies have found that neoadjuvant docetaxel is safe and well tolerated and does not result in any additional surgical complications. All studies demonstrated a certain degree of preoperative PSA reduction though there were few to no complete pathologic responses noted after prostatectomy. To date, the largest study published has been a multi-institutional phase II study, which coadministered docetaxel (35 mg/m<Superscript>2</Superscript> weekly for 6 out of 8 weeks for three doses) with combined androgen deprivation prior to prostatectomy [<CitationRef CitationID="CR91_12">91</CitationRef>]. A total of 72 high-risk patients were treated though four did not complete the protocol due to toxicity (two hypersensitivity reactions and two pneumonitides). Ultimately 64 patients underwent prostatectomy after completing neoadjuvant treatment. There were two postoperative complications: one postoperative myocardial infarction and one DVT. On pathology, four patients had regional lymph node involvement, and 275 had positive margins. Two patients were downstaged to pT0. At a median follow-up of 42.7 months, 30% of patients had a PSA recurrence; median PSA recurrence-free survival (RFS) had not yet been met at the time of publication. Though, on univariate analysis, Gleason score and pathologic stage were associated with PSA RFS, while on multivariate analysis, only Gleason score remained significant. Three patients died of their disease, two of whom had positive nodes at the time of surgery. A phase III, multi-institutional study, PUNCH (Preoperative Use of Neoadjuvant ChemoHormonal Therapy, CALGB 90203) by the Cancer and Leukemia Group B is currently underway and is comparing the impact of neoadjuvant docetaxel and estramustine vs. prostatectomy alone on 5-year PSA RFS [<CitationRef CitationID="CR92_12">92</CitationRef>].</Para>
            <Para TextBreak="No">Although several studies have examined the effect of adjuvant radiation and ADT in prostatectomy patients, there is a marked paucity of adjuvant chemotherapy studies despite the known success of adjuvant treatments for non-small cell lung cancer, colon cancer, and breast cancer. Lack of these studies is not due to lack of trial initiation; SWOG 9921 was closed in 2007 after three patients treated with mitoxantrone developed leukemia. TAX 3501 was a study comparing immediate and delayed ADT and six cycles of docetaxel (given every 3 weeks) after prostatectomy. This study, which randomized a total of 228 patients, was closed due to slow accrual [<CitationRef CitationID="CR93_12">93</CitationRef>]. A phase II pilot study, which treated 77 men with six weekly cycles of adjuvant docetaxel, recently reported a 26% grade 3 toxicity rate and a 4% grade 4 toxicity rate [<CitationRef CitationID="CR94_12">94</CitationRef>]. With a median follow-up of 29.2 months, there was a 60.5% rate of progression and a median PFS of 15.7 months. A total of seven patients died with four deaths due to prostate cancer. While these results are interesting, clearly randomized trials are needed. Currently, the VA Cooperative Studies Program Study 553 is the only phase III adjuvant taxane-based chemotherapy study accruing [<CitationRef CitationID="CR95_12">95</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec13">
            <Heading>Docetaxel and Radiation Therapy</Heading>
            <Para TextBreak="No">Patients with high-risk localized prostate cancer, who are ineligible or do not desire prostatectomy, most often undergo external beam radiation therapy (EBRT). EBRT is routinely administered with both neoadjuvant and adjuvant ADT. Even prior to demonstrating docetaxel’s efficacy in prostate cancer, interest in combining taxanes with radiation for other malignancies was evident. These studies largely stemmed from the fact that both docetaxel and EBRT induce cell cycle arrest and apoptosis in the G2 and M phases, and consistent with the hypothesis, preclinical data did suggest that docetaxel may sensitize tissues to the effects of radiation. In murine mammary carcinoma xenograft models, administration of docetaxel 48 h prior to a single dose of radiation enhanced tumor response to radiation by a factor of 2.33 [<CitationRef CitationID="CR96_12">96</CitationRef>]. The effect on normal tissues was minimal. In humans with localized high-risk disease, a phase I trial of weekly docetaxel administered concomitantly with a total of 70.2 Gy of radiation (fractionated 1.8 Gy daily) demonstrated that 20 mg/m<Superscript>2</Superscript> of docetaxel was the MTD for docetaxel administered with EBRT [<CitationRef CitationID="CR97_12">97</CitationRef>]. The dose-limiting toxicity in this study was grade 3 diarrhea. Four years later, phase I/II data were published [<CitationRef CitationID="CR98_12">98</CitationRef>]. Twenty men were enrolled, 17 of whom were also receiving ADT. The most frequent toxicities were grade 2 diarrhea, fatigue, urinary frequency, and constipation. There were no hematologic toxicities greater than grade 1, and only three patients experienced an interruption in treatment (two for dehydration and one for a nonsteroidal anti-inflammatory drug-induced gastrointestinal bleed). At a median follow-up of 11.7 months, the rate of PFS was 85%.</Para>
            <Para TextBreak="No">A third pilot study has since examined the feasibility of aggressive multimodal therapy after prostatectomy [<CitationRef CitationID="CR99_12">99</CitationRef>]. Twenty-eight high-risk prostate cancer patients underwent prostatectomy followed by six cycles of combination chemotherapy (either docetaxel and estramustine or docetaxel and carboplatin), followed by 5 years of ADT. Patients who had pT4 disease or more than one positive margin also received EBRT after chemotherapy. In this study, 20 patients received docetaxel and estramustine while 8 received docetaxel and carboplatin; 7 of the patients also received EBRT. The most frequent major toxicity was grade 3–4 neutropenia in 65% and edema in 30%. Of the patients receiving estramustine, 25% developed DVTs. At a mean follow-up of 31 months, no patient experienced a PSA recurrence, and 93% were free of disease progression. Interestingly, there were two deaths in the cohort, both of whom died of prostate cancer, but neither of whom had PSA relapse. The Radiation Therapy Oncology Group (RTOG) is currently enrolling patients into a randomized phase III study (RTOG 0521), which will compare patients treated with ADT and EBRT to patients receiving six cycles of docetaxel prednisone after EBRT and ADT [<CitationRef CitationID="CR100_12">100</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec14" Type="Conclusion">
            <Heading>Conclusions</Heading>
            <Para TextBreak="No">Docetaxel-based chemotherapy is the first treatment regimen demonstrated to increase survival in patients with CRPC. The exact timing of treatment in the spectrum of CRPC and duration of docetaxel therapy remains controversial. Ongoing studies are evaluating the optimal combination of docetaxel with targeted therapy to improve survival. Aggressive accrual into randomized, controlled trials should be encouraged in patients with CRPC.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_12.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_12">
              <CitationNumber>1.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Jemal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Siegel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Ward</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Cancer statistics, 2008</ArticleTitle>
                <JournalTitle>CA: Cancer J Clin</JournalTitle>
                <VolumeID>58</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>71</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.3322/CA.2007.0010</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: Cancer J Clin 2008;58(2):71–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_12">
              <CitationNumber>2.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Loblaw</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KS</Initials>
                  <FamilyName>Virgo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Nam</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>1596</FirstPage>
                <LastPage>605</LastPage>
                <Occurrence Type="PID">
                  <Handle>17404365</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2006.10.1949</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXlsVynurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25(12):1596–605.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_12">
              <CitationNumber>3.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Lucas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">The case for early chemotherapy for the treatment of metastatic disease</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>176</VolumeID>
                <IssueID>6 Pt 2</IssueID>
                <FirstPage>S72</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>17084173</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2006.06.077</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xhtlajt7nP</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lucas A, Petrylak DP. The case for early chemotherapy for the treatment of metastatic disease. J Urol 2006;176(6 Pt 2): S72–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_12">
              <CitationNumber>4.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Conaway</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>2506</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>10561316</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXltlyltL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17(8):2506–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_12">
              <CitationNumber>5.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Osoba</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Stockler</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1756</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>8656243</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XjslOrsr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_12">
              <CitationNumber>6.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Parness</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1981</Year>
                <ArticleTitle Language="En">Taxol binds to polymerized tubulin in vitro</ArticleTitle>
                <JournalTitle>J Cell Biol</JournalTitle>
                <VolumeID>91</VolumeID>
                <IssueID>2 Pt 1</IssueID>
                <FirstPage>479</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="PID">
                  <Handle>6118377</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1083/jcb.91.2.479</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL38Xit12g</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91(2 Pt 1):479–87.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_12">
              <CitationNumber>7.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PB</Initials>
                  <FamilyName>Schiff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Fant</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1979</Year>
                <ArticleTitle Language="En">Promotion of microtubule assembly in vitro by taxol</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>277</VolumeID>
                <IssueID>5698</IssueID>
                <FirstPage>665</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>423966</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/277665a0</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE1MXkvVCitrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277(5698):665–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_12">
              <CitationNumber>8.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PB</Initials>
                  <FamilyName>Schiff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1980</Year>
                <ArticleTitle Language="En">Taxol stabilizes microtubules in mouse fibroblast cells</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>77</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>1561</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>6103535</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.77.3.1561</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL3cXktVSnt7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77(3):1561–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_12">
              <CitationNumber>9.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Foa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Norton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AD</Initials>
                  <FamilyName>Seidman</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity</ArticleTitle>
                <JournalTitle>Int J Clin Lab Res</JournalTitle>
                <VolumeID>24</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>6</FirstPage>
                <LastPage>14</LastPage>
                <Occurrence Type="PID">
                  <Handle>7910054</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/BF02592403</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c3jsF2jtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Foa R, Norton L, Seidman AD. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res 1994;24(1):6–14.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_12">
              <CitationNumber>10.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BJ</Initials>
                  <FamilyName>Roth</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BY</Initials>
                  <FamilyName>Yeap</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Wilding</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Kasimis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>McLeod</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Loehrer</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>72</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>2457</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>8104680</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(19931015)72:8&lt;2457::AID-CNCR2820720825&gt;3.0.CO;2-Z</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c%2Fgs1SmsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993;72(8):2457–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_12">
              <CitationNumber>11.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KD</Initials>
                  <FamilyName>Tew</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Glusker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Hartley-Asp</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Hudes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Speicher</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug</ArticleTitle>
                <JournalTitle>Pharmcol Ther</JournalTitle>
                <VolumeID>56</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>323</FirstPage>
                <LastPage>39</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0163-7258(92)90023-S</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXksVSjsLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tew KD, Glusker JP, Hartley-Asp B, Hudes G, Speicher LA. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmcol Ther 1992;56(3):323–39.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_12">
              <CitationNumber>12.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Speicher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Barone</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KD</Initials>
                  <FamilyName>Tew</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>52</VolumeID>
                <IssueID>16</IssueID>
                <FirstPage>4433</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>1353706</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38XmtVCltbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 1992;52(16):4433–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_12">
              <CitationNumber>13.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Haas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Roth</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Garay</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>58</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>59</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>11445480</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(01)01011-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3MzptFCrsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Haas N, Roth B, Garay C, et al. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology 2001;58(1):59–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_12">
              <CitationNumber>14.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AD</Initials>
                  <FamilyName>Seidman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>Dershaw</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Curley</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>147</VolumeID>
                <IssueID>3 Pt 2</IssueID>
                <FirstPage>931</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>1371564</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK387mslCmsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 1992;147(3 Pt 2):931–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_12">
              <CitationNumber>15.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Hudes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Greenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Krigel</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>1754</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>1383436</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s%2FhvFCgtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992;10(11):1754–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_12">
              <CitationNumber>16.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Hudes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Obasaju</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Chapman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gallo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>McAleer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Greenberg</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>3 Suppl 6</IssueID>
                <FirstPage>6</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="PID">
                  <Handle>7597435</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2MzitVGrtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hudes GR, Obasaju C, Chapman A, Gallo J, McAleer C, Greenberg R. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer. Semin Oncol 1995;22(3 Suppl 6):6–11.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_12">
              <CitationNumber>17.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Hudes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Nathan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Khater</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>15</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>3156</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>9294479</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmt1SqtrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997;15(9):3156–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_12">
              <CitationNumber>18.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Ringel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>83</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>288</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>1671606</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/83.4.288</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3MXisVSjtLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991;83(4):288–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_12">
              <CitationNumber>19.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Vidensek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Lim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Campbell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Carlson</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">Taxol content in bark, wood, root, leaf, twig, and seedling from several Taxus species</ArticleTitle>
                <JournalTitle>J Nat Prod</JournalTitle>
                <VolumeID>53</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1609</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>1982448</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1021/np50072a039</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3MXlvV2gtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vidensek N, Lim P, Campbell A, Carlson C. Taxol content in bark, wood, root, leaf, twig, and seedling from several Taxus species. J Nat Prod1990;53(6):1609–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_12">
              <CitationNumber>20.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Bissery</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Guenard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Gueritte-Voegelein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Lavelle</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>51</VolumeID>
                <IssueID>18</IssueID>
                <FirstPage>4845</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>1680023</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3MXmt1aqsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991;51(18):4845–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_12">
              <CitationNumber>21.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Vogel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SG</Initials>
                  <FamilyName>Hilsenbeck</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Depenbrock</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents</ArticleTitle>
                <JournalTitle>Eur J Cancer</JournalTitle>
                <VolumeID>29A</VolumeID>
                <IssueID>14</IssueID>
                <FirstPage>2009</FirstPage>
                <LastPage>14</LastPage>
                <Occurrence Type="PID">
                  <Handle>7904173</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0959-8049(93)90463-P</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXis1Skt78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vogel M, Hilsenbeck SG, Depenbrock H, et al. Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer 1993;29A(14):2009–14.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_12">
              <CitationNumber>22.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Lavelle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Bissery</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Combeau</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JF</Initials>
                  <FamilyName>Riou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Vrignaud</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Andre</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Preclinical evaluation of docetaxel (Taxotere)</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>2 Suppl 4</IssueID>
                <FirstPage>3</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXmt1Onu7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, Andre S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995;22(2 Suppl 4):3–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_12">
              <CitationNumber>23.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Budman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Calabro</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Kreis</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro</ArticleTitle>
                <JournalTitle>Anticancer Drugs</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>1011</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>12439335</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00001813-200211000-00005</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XoslGls7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Budman DR, Calabro A, Kreis W. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 2002;13(10):1011–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_12">
              <CitationNumber>24.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Kreis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Budman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Calabro</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines</ArticleTitle>
                <JournalTitle>Br J Urol</JournalTitle>
                <VolumeID>79</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>196</FirstPage>
                <LastPage>202</LastPage>
                <Occurrence Type="PID">
                  <Handle>9052470</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1464-410X.1997.06310.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXhsFeqtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997;79(2):196–202.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_12">
              <CitationNumber>25.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Picus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Schultz</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>5 Suppl 17</IssueID>
                <FirstPage>14</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10604263</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXivVahtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999;26(5 Suppl 17):14–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_12">
              <CitationNumber>26.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Macarthur</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>O’Connor</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>958</FirstPage>
                <LastPage>67</LastPage>
                <Occurrence Type="PID">
                  <Handle>10071290</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXhvFGgu7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Macarthur RB, O’Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999;17(3):958–67.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_12">
              <CitationNumber>27.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Kreis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Budman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Fetten</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AL</Initials>
                  <FamilyName>Gonzales</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Barile</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Vinciguerra</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma</ArticleTitle>
                <JournalTitle>Ann Oncol</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>33</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10076719</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1023/A:1008354600497</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M7ns1Sitw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999;10(1):33–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_12">
              <CitationNumber>28.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Macarthur</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>O’Connor</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>5 Suppl 17</IssueID>
                <FirstPage>28</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>10604266</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXivVahtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Macarthur R, O’Connor J, et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 1999;26(5 Suppl 17):28–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_12">
              <CitationNumber>29.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Savarese</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Hars</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Kreis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Vogelzang</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>5 Suppl 17</IssueID>
                <FirstPage>39</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>10604268</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXivVahuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Savarese D, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. Semin Oncol 1999;26(5 Suppl 17):39–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_12">
              <CitationNumber>30.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer</ArticleTitle>
                <JournalTitle>New Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <IssueID>15</IssueID>
                <FirstPage>1502</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470213</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa040720</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004;351(15):1502–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_12">
              <CitationNumber>31.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Berthold</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Pond</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Soban</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Eisenberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>242</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>18182665</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2007.12.4008</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXitVWitLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_12">
              <CitationNumber>32.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Berthold</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Pond</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Eisenberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa</ArticleTitle>
                <JournalTitle>Ann Oncol</JournalTitle>
                <VolumeID>19</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>1749</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>18487550</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/annonc/mdn288</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD1cnhslKjsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19(10):1749–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_12">
              <CitationNumber>33.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Saad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Ruether</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Ernst</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>102</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>551</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>18510661</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1464-410X.2008.07733.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtFSlurjJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Saad F, Ruether D, Ernst S, et al. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. BJU Int 2008;102(5):551–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_12">
              <CitationNumber>34.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Slaviero</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Clarke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>McLachlan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EY</Initials>
                  <FamilyName>Blair</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LP</Initials>
                  <FamilyName>Rivory</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Population pharmacokinetics of weekly docetaxel in patients with advanced cancer</ArticleTitle>
                <JournalTitle>Br J Clin Pharmacol</JournalTitle>
                <VolumeID>57</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>44</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>14678339</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1365-2125.2003.01956.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXotlOjug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Slaviero KA, Clarke SJ, McLachlan AJ, Blair EY, Rivory LP. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 2004;57(1):44–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_12">
              <CitationNumber>35.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Hainsworth</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Practical aspects of weekly docetaxel administration schedules</ArticleTitle>
                <JournalTitle>Oncologist</JournalTitle>
                <VolumeID>9</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>538</FirstPage>
                <LastPage>45</LastPage>
                <Occurrence Type="PID">
                  <Handle>15477638</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1634/theoncologist.9-5-538</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXps1amtr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. Oncologist 2004;9(5):538–45.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_12">
              <CitationNumber>36.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Chemotherapy for androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>World J Urol</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>10</FirstPage>
                <LastPage>3</LastPage>
                <Occurrence Type="PID">
                  <Handle>15685445</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s00345-004-0482-0</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXit1OlsLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP. Chemotherapy for androgen-independent prostate cancer. World J Urol 2005;23(1):10–3.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_12">
              <CitationNumber>37.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer</ArticleTitle>
                <JournalTitle>New Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <IssueID>15</IssueID>
                <FirstPage>1513</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470214</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa041318</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 2004;351(15):1513–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_12">
              <CitationNumber>38.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Moinpour</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Jiang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <IssueID>18</IssueID>
                <FirstPage>2828</FirstPage>
                <LastPage>35</LastPage>
                <Occurrence Type="PID">
                  <Handle>16782921</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.04.8207</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XntV2gsr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berry DL, Moinpour CM, Jiang CS, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 2006;24(18):2828–35.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_12">
              <CitationNumber>39.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">New paradigms for advanced prostate cancer</ArticleTitle>
                <JournalTitle>Rev Urol</JournalTitle>
                <VolumeID>9</VolumeID>
                <IssueID>Suppl 2</IssueID>
                <FirstPage>S3</FirstPage>
                <LastPage>S12</LastPage>
                <Occurrence Type="PID">
                  <Handle>17554403</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP. New paradigms for advanced prostate cancer. Rev Urol 2007;9(Suppl 2):S3–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_12">
              <CitationNumber>40.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ZN</Initials>
                  <FamilyName>Oltvai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Milliman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Korsmeyer</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>74</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>609</FirstPage>
                <LastPage>19</LastPage>
                <Occurrence Type="PID">
                  <Handle>8358790</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0092-8674(93)90509-O</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXms1eqtbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74(4):609–19.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_12">
              <CitationNumber>41.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Perlman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MW</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Walsh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Buttyan</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis</ArticleTitle>
                <JournalTitle>Cell Death Differ</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>48</FirstPage>
                <LastPage>54</LastPage>
                <Occurrence Type="PID">
                  <Handle>10200547</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.cdd.4400453</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXhsF2rsbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Perlman H, Zhang X, Chen MW, Walsh K, Buttyan R. An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Differ 1999;6(1):48–54.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_12">
              <CitationNumber>42.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BJ</Initials>
                  <FamilyName>Eigl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SE</Initials>
                  <FamilyName>Eggener</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Baybik</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>4905</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="PID">
                  <Handle>16000589</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-04-2140</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXlvVGgsLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Eigl BJ, Eggener SE, Baybik J, et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005;11(13):4905–11.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_12">
              <CitationNumber>43.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Tang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Khan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Goloubeva</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>169</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>16397039</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-05-1388</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xht1GlsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tang Y, Khan MA, Goloubeva O, et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 2006;12(1):169–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_12">
              <CitationNumber>44.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Dawson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Amin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>2789</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="PID">
                  <Handle>15837994</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.07.152</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXktleqtrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hussain A, Dawson N, Amin P, et al. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol 2005;23(12):2789–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_12">
              <CitationNumber>45.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Dakhil</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Modiano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Gregurich</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Asmar</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>168</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>2439</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>12441935</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)64163-8</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XovVehsbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002;168(6):2439–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_12">
              <CitationNumber>46.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Hamberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Verhagen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?</ArticleTitle>
                <JournalTitle>Eur J Cancer</JournalTitle>
                <VolumeID>44</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>1193</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>18448326</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.ejca.2008.04.005</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD1czlslOjuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hamberg P, Verhagen PC, de Wit R. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer 2008;44(9):1193–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_12">
              <CitationNumber>47.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Armstrong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ES</Initials>
                  <FamilyName>Garrett-Mayer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YC</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Eisenberger</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>21</IssueID>
                <FirstPage>6396</FirstPage>
                <LastPage>403</LastPage>
                <Occurrence Type="PID">
                  <Handle>17975152</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-07-1036</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1CgtbzN</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007;13(21):6396–403.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_12">
              <CitationNumber>48.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Oudard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Banu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Scotte</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients</ArticleTitle>
                <JournalTitle>Ann Oncol</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>1828</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>17846024</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/annonc/mdm332</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD2snmvFWktQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Oudard S, Banu E, Scotte F, et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007;18(11):1828–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_12">
              <CitationNumber>49.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1971</Year>
                <ArticleTitle Language="En">Tumor angiogenesis: therapeutic implications</ArticleTitle>
                <JournalTitle>New Engl J Med</JournalTitle>
                <VolumeID>285</VolumeID>
                <IssueID>21</IssueID>
                <FirstPage>1182</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>4938153</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM197111182852108</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaE38%2FgvVCqsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971;285(21):1182–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_12">
              <CitationNumber>50.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Sweeney</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KD</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SE</Initials>
                  <FamilyName>Sissons</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>3369</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>11309294</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjtFSjur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61(8):3369–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_12">
              <CitationNumber>51.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Gasparini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Longo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Fanelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Teicher</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1295</FirstPage>
                <LastPage>311</LastPage>
                <Occurrence Type="PID">
                  <Handle>15718328</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.10.022</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXitl2gu74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005;23(6):1295–311.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_12">
              <CitationNumber>52.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Lorenzo</FamilyName>
                  <Particle>Di</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Fossa</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>54</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1089</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>18276061</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.eururo.2008.01.082</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008;54(5):1089–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_12">
              <CitationNumber>53.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Zhu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LG</Initials>
                  <FamilyName>Corral</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YW</Initials>
                  <FamilyName>Fleming</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Stein</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Immunomodulatory drugs Revlimid<Superscript>®</Superscript> (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation</ArticleTitle>
                <JournalTitle>Cancer Immunol Immunother</JournalTitle>
                <VolumeID>57</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>1849</FirstPage>
                <LastPage>59</LastPage>
                <Occurrence Type="PID">
                  <Handle>18392823</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s00262-008-0512-7</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtFCgu7jM</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid<Superscript>®</Superscript> (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008;57(12):1849–59.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_12">
              <CitationNumber>54.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Sanborn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Cooney</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Dowlati</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>355</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>18470481</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s10637-008-9137-0</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXnsVKiu7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sanborn SL, Cooney MM, Dowlati A, et al. Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs 2008;26(4):355–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_12">
              <CitationNumber>55.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Ning</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Fulley</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (DOC) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC)</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>abstr 5000</FirstPage>
              </BibArticle>
              <BibUnstructured>Ning Y, Arlen P, Fulley J, et al. Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (DOC) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). J Clin Oncol 2008;26:abstr 5000.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_12">
              <CitationNumber>56.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Cumashi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Tinari</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Rossi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts</ArticleTitle>
                <JournalTitle>Cancer Lett</JournalTitle>
                <VolumeID>270</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>229</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>18586384</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.canlet.2008.05.007</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtFekt77N</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cumashi A, Tinari N, Rossi C, et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008;270(2):229–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_12">
              <CitationNumber>57.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Guerin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Formento</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Lo Nigro</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Cancer Res Clin Oncol</JournalTitle>
                <VolumeID>134</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>51</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>17593391</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s00432-007-0247-4</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1KrurrF</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Guerin O, Formento P, Lo Nigro C, et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 2008;134(1):51–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_12">
              <CitationNumber>58.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>George</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Liu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Wilding</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone refractor prostate cancer (mHRPC) – preliminary results</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>abstr 5131</FirstPage>
              </BibArticle>
              <BibUnstructured>George D, Liu G, Wilding G, et al. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone refractor prostate cancer (mHRPC) – preliminary results. J Clin Oncol 2008;26:abstr 5131.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_12">
              <CitationNumber>59.</CitationNumber>
              <BibUnstructured>ClinicalTrials.gov. Accessed 2008, at <ExternalRef>
                  <RefSource>http://www.clinicaltrials.gov</RefSource>
                  <RefTarget Address="http://www.clinicaltrials.gov" TargetType="URL"/>
                </ExternalRef>
              </BibUnstructured>
            </Citation>
            <Citation ID="CR60_12">
              <CitationNumber>60.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>YR</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Wigington</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Strugnell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Knutson</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug</ArticleTitle>
                <JournalTitle>Anticancer Res</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>6B</IssueID>
                <FirstPage>4333</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16309237</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXht12itL7O</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wang YR, Wigington DP, Strugnell SA, Knutson JC. Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug. Anticancer Res 2005;25(6B):4333–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_12">
              <CitationNumber>61.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SE</Initials>
                  <FamilyName>Blutt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TC</Initials>
                  <FamilyName>Polek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LV</Initials>
                  <FamilyName>Stewart</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MW</Initials>
                  <FamilyName>Kattan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NL</Initials>
                  <FamilyName>Weigel</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>60</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>779</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>10706079</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXhs1Sitbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 2000;60(4):779–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_12">
              <CitationNumber>62.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Hershberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Modzelewski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Rueger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Johnson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Trump</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Calcitriol (1, 25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>1043</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>11309356</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjs1elt7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001;7(4):1043–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_12">
              <CitationNumber>63.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KM</Initials>
                  <FamilyName>Hough</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Garzotto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Lowe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Henner</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Weekly high-dose calcitriol and docetaxel in advanced prostate cancer</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>28</VolumeID>
                <IssueID>4 Suppl 15</IssueID>
                <FirstPage>49</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>11685729</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0093-7754(01)90155-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXotVemtr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 2001;28(4 Suppl 15):49–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_12">
              <CitationNumber>64.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Ryan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Venner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>669</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>17308271</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2006.06.8197</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjt1Kgu7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25(6):669–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_12">
              <CitationNumber>65.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Bagnato</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Rosano</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">The endothelin axis in cancer</ArticleTitle>
                <JournalTitle>Int J Biochem Cell Biol</JournalTitle>
                <VolumeID>40</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>1443</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>18325824</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.biocel.2008.01.022</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXlslGqurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bagnato A, Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol 2008;40(8):1443–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_12">
              <CitationNumber>66.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Jimeno</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Targeting bone metastasis in prostate cancer with endothelin receptor antagonists</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>20 Pt 2</IssueID>
                <FirstPage>6296s</FirstPage>
                <LastPage>300s</LastPage>
                <Occurrence Type="PID">
                  <Handle>17062717</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-06-0929</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFWhtr7P</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006;12(20 Pt 2):6296s–300s.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_12">
              <CitationNumber>67.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Jimeno</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer</ArticleTitle>
                <JournalTitle>Expert Rev Anticancer Ther</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>419</FirstPage>
                <LastPage>27</LastPage>
                <Occurrence Type="PID">
                  <Handle>16001950</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1586/14737140.5.3.419</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXmtF2it7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jimeno A, Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 2005;5(3):419–27.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_12">
              <CitationNumber>68.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Padley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Breul</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>679</FirstPage>
                <LastPage>89</LastPage>
                <Occurrence Type="PID">
                  <Handle>12586806</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2003.04.176</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVGrurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21(4):679–89.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_12">
              <CitationNumber>69.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Banerjee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>3818</FirstPage>
                <LastPage>26</LastPage>
                <Occurrence Type="PID">
                  <Handle>17440096</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-06-3879</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXkt1KitLo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Banerjee S, Hussain M, Wang Z, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007;67(8):3818–26.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_12">
              <CitationNumber>70.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Zou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Anisowicz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Hendrix</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>263</VolumeID>
                <IssueID>5146</IssueID>
                <FirstPage>526</FirstPage>
                <LastPage>-9</LastPage>
                <Occurrence Type="PID">
                  <Handle>8290962</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.8290962</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXhsFOntb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994;263(5146):526-9.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_12">
              <CitationNumber>71.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Luo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Tan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Ricono</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>446</VolumeID>
                <IssueID>7136</IssueID>
                <FirstPage>690</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>17377533</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nature05656</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjslOlsLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007;446(7136):690–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_12">
              <CitationNumber>72.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Roudier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Jones</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Armstrong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Canon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>Dougall</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis</ArticleTitle>
                <JournalTitle>Mol Cancer Ther</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>2160</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>18606716</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1535-7163.MCT-08-0046</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXoslCnsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008;7(7):2160–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_12">
              <CitationNumber>73.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Dreicer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Agus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Webb</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Roth</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>1208</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>17317831</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-06-2046</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhvF2hsbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dreicer R, Petrylak D, Agus D, Webb I, Roth B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 2007;13(4):1208–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_12">
              <CitationNumber>74.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Cao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KT</Initials>
                  <FamilyName>Shiverick</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Namiki</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation</ArticleTitle>
                <JournalTitle>World J Urol</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>509</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="PID">
                  <Handle>18594829</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s00345-008-0289-5</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXht1Sqs7jF</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cao W, Shiverick KT, Namiki K, et al. Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World J Urol 2008;26(5):509–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_12">
              <CitationNumber>75.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Morris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Beekman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Phase II study of bortezomib for castrate metastatic prostate cancer</ArticleTitle>
                <JournalTitle>Proc Am Soc Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>411S(abstract 4633)</FirstPage>
              </BibArticle>
              <BibUnstructured>Morris M, Beekman K, Kelly W, et al. Phase II study of bortezomib for castrate metastatic prostate cancer. Proc Am Soc Clin Oncol 2005;23:411S(abstract 4633).</BibUnstructured>
            </Citation>
            <Citation ID="CR76_12">
              <CitationNumber>76.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CN</Initials>
                  <FamilyName>Papandreou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>Daliani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Nix</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2108</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>15169797</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2004.02.106</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVWlsLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22(11):2108–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_12">
              <CitationNumber>77.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Kaufman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Manola</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2122</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>15169798</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2004.08.083</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVWlsbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22(11):2122–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_12">
              <CitationNumber>78.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kaufman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Manola</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: follow up clinical results from ECOG 7897</ArticleTitle>
                <JournalTitle>Proc Am Soc Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>4501a</FirstPage>
              </BibArticle>
              <BibUnstructured>Kaufman H, Wang W, Manola J, et al. Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: follow up clinical results from ECOG 7897. Proc Am Soc Clin Oncol 2005;24:4501a.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_12">
              <CitationNumber>79.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Parker</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>1260</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16489082</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-05-2059</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhsFaltb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12(4):1260–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_12">
              <CitationNumber>80.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CT</Initials>
                  <FamilyName>Garnett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Hodge</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>3536</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>18519787</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-07-4025</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmslygtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14(11):3536–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_12">
              <CitationNumber>81.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Roehl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Han</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CG</Initials>
                  <FamilyName>Ramos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Antenor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Catalona</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3, 478 consecutive patients: long-term results</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>172</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>910</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>15310996</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.ju.0000134888.22332.bb</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172(3):910–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_12">
              <CitationNumber>82.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Pickles</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Morgan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Morton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Souhami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Warde</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Lukka</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus Statement</ArticleTitle>
                <JournalTitle>Can Urol Assoc J (Journal de l’Association des urologues du Canada)</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>95</FirstPage>
                <LastPage>9</LastPage>
              </BibArticle>
              <BibUnstructured>Pickles T, Morgan S, Morton G, Souhami L, Warde P, Lukka H. Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus Statement. Can Urol Assoc J (Journal de l’Association des urologues du Canada) 2008;2(2):95–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_12">
              <CitationNumber>83.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Sonpavde</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KN</Initials>
                  <FamilyName>Chi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Powles</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>110</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>2628</FirstPage>
                <LastPage>39</LastPage>
                <Occurrence Type="PID">
                  <Handle>17941029</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.23085</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXitVOitg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sonpavde G, Chi KN, Powles T, et al. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer 2007;110(12):2628–39.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_12">
              <CitationNumber>84.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Carson</FamilyName>
                  <Suffix>III</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Zincke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DC</Initials>
                  <FamilyName>Utz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Cupps</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GM</Initials>
                  <FamilyName>Farrow</FamilyName>
                </BibAuthorName>
                <Year>1980</Year>
                <ArticleTitle Language="En">Radical prostatectomy after radiotherapy for prostatic cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>124</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>237</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7401237</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Carson CC III, Zincke H, Utz DC, Cupps RE, Farrow GM. Radical prostatectomy after radiotherapy for prostatic cancer. J Urol 1980;124(2):237–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_12">
              <CitationNumber>85.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Garcia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Klein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Magi-Galluzzi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Elson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Triozzi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Dreicer</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>3052</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>18483371</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-07-4731</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmtVCmtb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Garcia JA, Klein EA, Magi-Galluzzi C, Elson P, Triozzi P, Dreicer R. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res 2008;14(10):3052–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_12">
              <CitationNumber>86.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DC</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BF</Initials>
                  <FamilyName>El-Rayes</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>774</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>12670564</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(02)02519-0</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hussain M, Smith DC, El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology 2003;61(4):774–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_12">
              <CitationNumber>87.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Dreicer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Magi-Galluzzi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Zhou</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>63</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1138</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>15183967</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urology.2004.01.040</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004;63(6):1138–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_12">
              <CitationNumber>88.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PG</Initials>
                  <FamilyName>Febbo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Richie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>George</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>14</IssueID>
                <FirstPage>5233</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>16033841</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-05-0299</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXmt12qur0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11(14):5233–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_12">
              <CitationNumber>89.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Garzotto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Myrthue</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Higano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer</ArticleTitle>
                <JournalTitle>Urol Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>254</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16678060</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urolonc.2005.11.034</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XktVGgsL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Garzotto M, Myrthue A, Higano CS, Beer TM. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 2006;24(3):254–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_12">
              <CitationNumber>90.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Friedman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Dunn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Wood</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>179(</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>911</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2007.10.064</Handle>
                </Occurrence>
                <BibComments>discussion 5–6</BibComments>
              </BibArticle>
              <BibUnstructured>Friedman J, Dunn RL, Wood D, et al. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 2008;179(3):911–5; discussion 5–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_12">
              <CitationNumber>91.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KN</Initials>
                  <FamilyName>Chi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Chin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Winquist</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Klotz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Saad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Gleave</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>180</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>565</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>18554663</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2008.04.012</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXpsFyiu78%3D</Handle>
                </Occurrence>
                <BibComments>discussion 70</BibComments>
              </BibArticle>
              <BibUnstructured>Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008;180(2):565–70; discussion 70.</BibUnstructured>
            </Citation>
            <Citation ID="CR92_12">
              <CitationNumber>92.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Eastham</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GD</Initials>
                  <FamilyName>Grossfeld</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>62</VolumeID>
                <IssueID>Suppl 1</IssueID>
                <FirstPage>55</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>14747042</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urology.2003.09.052</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;62(Suppl 1):55–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR93_12">
              <CitationNumber>93.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Eisenberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kattan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Kibel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Sternberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Impact of central pathology review (CPR) of radical prostatectomy (RP) specimens for patient selection in the surgical adjuvant trial in prostate cancer (PCa) TAX-3501</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>abstr 5128</FirstPage>
              </BibArticle>
              <BibUnstructured>Eisenberger M, Kattan M, Kibel A, Sternberg C, Epstein J. Impact of central pathology review (CPR) of radical prostatectomy (RP) specimens for patient selection in the surgical adjuvant trial in prostate cancer (PCa) TAX-3501. J Clin Oncol 2008;26:abstr 5128.</BibUnstructured>
            </Citation>
            <Citation ID="CR94_12">
              <CitationNumber>94.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AS</Initials>
                  <FamilyName>Kibel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Rosenbaum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MW</Initials>
                  <FamilyName>Kattan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>177</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1777</FirstPage>
                <LastPage>81</LastPage>
                <Occurrence Type="PID">
                  <Handle>17437819</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2007.01.028</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXlsV2jtb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kibel AS, Rosenbaum E, Kattan MW, et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 2007;177(5):1777–81.</BibUnstructured>
            </Citation>
            <Citation ID="CR95_12">
              <CitationNumber>95.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Montgomery</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Lavori</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Garzotto</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>72</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>474</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>18407333</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urology.2008.02.050</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Montgomery B, Lavori P, Garzotto M, et al. Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology 2008;72(3):474–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR96_12">
              <CitationNumber>96.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Mason</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NR</Initials>
                  <FamilyName>Hunter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Milas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Abbruzzese</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Milas</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Docetaxel enhances tumor radioresponse in vivo</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>3</VolumeID>
                <IssueID>12 Pt 1</IssueID>
                <FirstPage>2431</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>9815644</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXisV2qtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997;3(12 Pt 1):2431–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR97_12">
              <CitationNumber>97.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Kumar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Perrotti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Weiss</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>1909</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>15143084</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2004.02.001</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXptlCksrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kumar P, Perrotti M, Weiss R, et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol 2004;22(10):1909–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR98_12">
              <CitationNumber>98.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Perrotti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Doyle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Kumar</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10)</ArticleTitle>
                <JournalTitle>Urol Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>276</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>18452819</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urolonc.2007.04.003</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXlslajs7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Perrotti M, Doyle T, Kumar P, et al. Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). Urol Oncol 2008;26(3):276–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR99_12">
              <CitationNumber>99.</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Ebrrahimi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Ruckle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Harper</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <BookTitle>Post prostatectomy multimodality adjuvant therapy for patients at high risk for prostate cancer relapse</BookTitle>
                <PublisherName>American Urologic Association Annual Meeting. Orlando</PublisherName>
                <PublisherLocation>In</PublisherLocation>
              </BibBook>
              <BibUnstructured>Ebrrahimi K, Ruckle H, Harper J, et al. Post prostatectomy multimodality adjuvant therapy for patients at high risk for prostate cancer relapse. In: American Urologic Association Annual Meeting, Orlando;2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR100_12">
              <CitationNumber>100.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Patel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HM</Initials>
                  <FamilyName>Sandler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>Pienta</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer</ArticleTitle>
                <JournalTitle>Clinical Genitourin Cancer</JournalTitle>
                <VolumeID>4</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>212</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.3816/CGC.2005.n.035</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Patel AR, Sandler HM, Pienta KJ. Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. Clinical Genitourin Cancer 2005;4(3):212–4.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
